Equity Profile

DXCM

DexCom, Inc.

Health CareHealth Care Equipment$28.1B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

DexCom, Inc. is a healthcare company specializing in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

Continuous Glucose Monitoring Sales

Sales growth in this segment is vital for assessing market demand and product adoption.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

DexCom, Inc. is a healthcare company specializing in continuous glucose monitoring systems for people with diabetes. As a leader in health care equipment, DexCom plays a crucial role in improving diabetes management through innovative technology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1 2026, DexCom reported an EPS of $0.56, exceeding expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Focus on expanding product offerings.
Commitment to enhancing customer support.
Plans to invest in research and development.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about DexCom's upcoming earnings, given the recent positive EPS surprises. However, the lack of specific guidance raises uncertainty.

Bull Case

If DexCom continues to show strong sales growth in its glucose monitoring products, it could lead to significant stock appreciation and positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a decline in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the sales figures for continuous glucose monitoring systems this quarter?

Sales performance in this key product area will indicate market demand and the effectiveness of DexCom's marketing strategies.

Will management provide any guidance on future revenue growth?

Clear guidance on revenue growth will help investors assess the company's outlook and potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for DexCom's new product launches to drive sales growth this quarter.

Supporting Evidence

Recent positive trends in diabetes management technology suggest a growing market.

Insider selling may indicate a strategic shift rather than a lack of confidence.

The options market is pricing in a larger move than historical averages suggest, indicating potential for surprise.

Key Risk

If continuous glucose monitoring sales exceed expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around whether DexCom can sustain its growth trajectory in a competitive market.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS falls below $0.50, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.8%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating heightened uncertainty around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$107,168.00

1,700 sh

1 insider

Net

$107,168.00

Net selling

Most Active Insiders· 1 open-market trade

EVP, Chief Legal OfficerBrown Michael Jon
$107,168.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations and raises guidance, history suggests the stock could rise by around 2.5% on the first day.

In-Line / Cautious

If results are in line but management is cautious, the stock may see minimal movement as investors digest the commentary.

Miss

If the company misses expectations, history indicates the stock could drop by about 0.65% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on product adoption rates for new glucose monitoring systems.
2Any updates on partnerships or collaborations that could enhance market reach.
3Insights into customer feedback and satisfaction levels.
4Management's outlook on competitive pressures in the healthcare equipment sector.
5Any commentary on cost management and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

DexCom, Inc. is a healthcare company specializing in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

Continuous Glucose Monitoring Sales

Sales growth in this segment is vital for assessing market demand and product adoption.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1 2026, DexCom reported an EPS of $0.56, exceeding expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Focus on expanding product offerings.
Commitment to enhancing customer support.
Plans to invest in research and development.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about DexCom's upcoming earnings, given the recent positive EPS surprises. However, the lack of specific guidance raises uncertainty.

Bull Case

If DexCom continues to show strong sales growth in its glucose monitoring products, it could lead to significant stock appreciation and positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a decline in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the sales figures for continuous glucose monitoring systems this quarter?

Sales performance in this key product area will indicate market demand and the effectiveness of DexCom's marketing strategies.

Will management provide any guidance on future revenue growth?

Clear guidance on revenue growth will help investors assess the company's outlook and potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for DexCom's new product launches to drive sales growth this quarter.

Supporting Evidence

Recent positive trends in diabetes management technology suggest a growing market.

Insider selling may indicate a strategic shift rather than a lack of confidence.

The options market is pricing in a larger move than historical averages suggest, indicating potential for surprise.

Key Risk

If continuous glucose monitoring sales exceed expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around whether DexCom can sustain its growth trajectory in a competitive market.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS falls below $0.50, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.8%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating heightened uncertainty around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$107,168.00

1,700 sh

1 insider

Net

$107,168.00

Net selling

Most Active Insiders· 1 open-market trade

EVP, Chief Legal OfficerBrown Michael Jon
$107,168.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations and raises guidance, history suggests the stock could rise by around 2.5% on the first day.

In-Line / Cautious

If results are in line but management is cautious, the stock may see minimal movement as investors digest the commentary.

Miss

If the company misses expectations, history indicates the stock could drop by about 0.65% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on product adoption rates for new glucose monitoring systems.
2Any updates on partnerships or collaborations that could enhance market reach.
3Insights into customer feedback and satisfaction levels.
4Management's outlook on competitive pressures in the healthcare equipment sector.
5Any commentary on cost management and operational efficiency.